Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer.

To keep genetic testing costs manageable, it is important to identify which patients should be selected for testing.

In this study, we compared expected costs and number of identified pathogenic variants in two scenarios: offering genetic testing to all men with metastatic prostate cancer versus testing only those with additional risk factors linked to a higher likelihood of carrying a pathogenic variant.